Impact of Dapagliflozin Adjunctive Therapy on Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and CKD Stage 2–5: A systematic review and meta-analysis

Authors

• Kanimozhi M, Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, India
• Manisha Bisht, Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, India
• Sikha Morang, Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, India
• Surabhi Thapliyal, Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, India
• Manbir S. Bassan, Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, India
• Shailendra Handu, Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, India

Abstract

This meta-analysis investigated efficacy of dapagliflozin as adjunctive therapy for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stages 2–5. A systematic search was conducted of selected databases for randomised controlled trials that reported the mean change in estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) from baseline. Out of 1,682 identified studies, 9 trials comprising 13,057 patients were included. A pooled estimate of 5 studies indicated that dapagliflozin did not affect eGFR; however, in 2 studies, it significantly reduced chronic eGFR decline compared to placebo (mean difference [MD] ± 2.74; 95% confidence interval [CI]: 1.55, 3.92; P <0.00001). Additionally, a pooled estimate of 4 studies showed that dapagliflozin significantly reduced UACR (MD −23.99%; 95% CI: −34.82–−13.15; P <0.0001; I² = 0%). Therefore, long-term use of dapagliflozin significantly attenuates eGFR decline and reduces albuminuria in patients with T2DM and CKD.

Article Type

Review

Publication Date

8-29-2024

First Page

317

Last Page

326

Creative Commons License

This work is licensed under a Creative Commons Attribution-No Derivative Works 4.0 International License.

Recommended Citation

M, Kanimozhi; Bisht, Manisha; Morang, Sikha; Thapliyal, Surabhi; Bassan, Manbir S.; and Handu, Shailendra (2024) "Impact of Dapagliflozin Adjunctive Therapy on Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and CKD Stage 2–5: A systematic review and meta-analysis," Sultan Qaboos University Medical Journal: Vol. 24: 317-326.
DOI: https://doi.org/10.18295/squmj.12.2023.093